PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21597702-9 1995 Our results suggested that flutamide reduces cytosolic androgen receptor levels and increases DNA synthesis. Flutamide 27-36 androgen receptor Mus musculus 55-72 10432234-13 1999 Flutamide, an AR antagonist, also blocked the enhancement of luciferase activity induced by EGF and testosterone, further confirming the role of AR in the effect of EGF and testosterone. Flutamide 0-9 androgen receptor Mus musculus 14-16 10432234-13 1999 Flutamide, an AR antagonist, also blocked the enhancement of luciferase activity induced by EGF and testosterone, further confirming the role of AR in the effect of EGF and testosterone. Flutamide 0-9 androgen receptor Mus musculus 145-147 9027406-8 1997 Moreover, morphogenetic effects depended on androgen receptor (AR) activation, since morphological changes were completely inhibited by flutamide. Flutamide 136-145 androgen receptor Mus musculus 44-61 9027406-8 1997 Moreover, morphogenetic effects depended on androgen receptor (AR) activation, since morphological changes were completely inhibited by flutamide. Flutamide 136-145 androgen receptor Mus musculus 63-65 7997435-6 1994 The growth of AR-transfectant cells was markedly inhibited in culture in the presence of testosterone, and the effect of testosterone was reduced by simultaneous addition of flutamide. Flutamide 174-183 androgen receptor Mus musculus 14-16 31676390-6 2020 The simultaneous treatment with testosterone and the androgen receptor antagonist, Flutamide, reduced these effects. Flutamide 83-92 androgen receptor Mus musculus 53-70 8070366-12 1994 Androgenic effects on hypothalamic AA and aromatase-IR cell numbers were dose-dependent and mediated via androgen receptor stimulation, since the observed effects were inhibited by the androgen-receptor antagonist flutamide. Flutamide 214-223 androgen receptor Mus musculus 105-122 33355366-8 2021 Finally, the increase in PMCA4 protein levels induced by testosterone was prevented by pre-treatment with the AR antagonist flutamide. Flutamide 124-133 androgen receptor Mus musculus 110-112 32916283-4 2020 We showed that conditional inducible H2A.Z deletion blocked memory-enhancing effects of androgen depletion (induced by gonadectomy), and of pharmacological inhibition of the androgen receptor with flutamide. Flutamide 197-206 androgen receptor Mus musculus 174-191 35353765-10 2022 Administration of the androgen receptor antagonist flutamide (200mg pellets) throughout the eight-week training program blocked the exercise induced protection against muscle pain in both sexes. Flutamide 51-60 androgen receptor Mus musculus 22-39 3964747-0 1985 Effect of a nonsteroidal antiandrogen, flutamide, on androgen receptor dynamics and ornithine decarboxylase gene expression in mouse kidney. Flutamide 39-48 androgen receptor Mus musculus 53-70 3964747-1 1985 The mechanisms by which nonsteroidal antiandrogens such as flutamide (alpha, alpha, alpha-trifluoro-2-methyl-4"-nitro-m-propionotoluidide) influence androgen receptor distribution and androgen-regulated gene expression are poorly understood. Flutamide 59-68 androgen receptor Mus musculus 149-166 3964747-1 1985 The mechanisms by which nonsteroidal antiandrogens such as flutamide (alpha, alpha, alpha-trifluoro-2-methyl-4"-nitro-m-propionotoluidide) influence androgen receptor distribution and androgen-regulated gene expression are poorly understood. Flutamide 70-137 androgen receptor Mus musculus 149-166 3964747-2 1985 Therefore, we studied acute and long-term effects of flutamide, administered alone or in combination with testosterone, on androgen receptor dynamics in mouse kidney. Flutamide 53-62 androgen receptor Mus musculus 123-140 3964747-6 1985 When 5 mg flutamide was given concomitantly with a submaximal dose of testosterone (0.1 mg), nuclear androgen receptor concentration was similar to that achieved with flutamide alone; this inhibitory effect of the antiandrogen was reversed by a 10-fold higher dose of testosterone. Flutamide 10-19 androgen receptor Mus musculus 101-118 3964747-8 1985 In these animals, flutamide administration decreased nuclear androgen receptor concentration with an initial half-life of about 3.3 h. This half-life was similar to that after cycloheximide administration, but significantly longer than that measured (1.3 h) upon removal of the implant. Flutamide 18-27 androgen receptor Mus musculus 61-78 3964747-13 1985 We conclude that 1) nuclear androgen receptor turnover in mouse kidney is a relatively rapid process and 2) nonsteroidal antiandrogens such as flutamide have an intrinsic ability to form Flutamide 143-152 androgen receptor Mus musculus 28-45 31948482-12 2020 Treatment with the androgen receptor antagonist flutamide reduced blood pressure and vascular hypertrophy in castrated Ang II-infused mice injected with 6beta-OHT. Flutamide 48-57 androgen receptor Mus musculus 19-36 30849180-4 2019 EXPERIMENTAL APPROACH: The androgen receptor antagonist, flutamide, was administered to presymptomatic SOD1G93A mice as a slow-release subcutaneous implant (5 mg day-1 ). Flutamide 57-66 androgen receptor Mus musculus 27-44 31544355-9 2019 In intact males, flutamide, an androgen receptor inhibitor, had similar effects to castration. Flutamide 17-26 androgen receptor Mus musculus 31-48 29471436-5 2018 C57BL/6 female mice were subcutaneously implanted with LET or placebo control and subsequently treated with the nonsteroidal AR antagonist flutamide or vehicle control. Flutamide 139-148 androgen receptor Mus musculus 125-127 30653980-7 2019 To test this hypothesis, intact males were infused with the androgen receptor antagonist flutamide into the DH after object training. Flutamide 89-98 androgen receptor Mus musculus 60-77 31096217-6 2019 To block the action of AR, we pretreated C2C12 myotubes with flutamide. Flutamide 61-70 androgen receptor Mus musculus 23-25 31096217-11 2019 Of interest, we found that myostatin was clearly inhibited by EPS, and its inhibition was significantly abrogated when AR was blocked by flutamide. Flutamide 137-146 androgen receptor Mus musculus 119-121 28901488-4 2017 All cells were divided into four groups, as follows: Control group, testosterone group, androgen receptor antagonist-flutamide group and flutamide + testosterone group. Flutamide 117-126 androgen receptor Mus musculus 88-105 29545336-8 2018 Treatment of male mice with the pharmacological AR antagonist flutamide reduced monocyte recruitment in mice. Flutamide 62-71 androgen receptor Mus musculus 48-50 28901488-5 2017 Flutamide was used in the present study as it blocks the effects of the androgen receptor. Flutamide 0-9 androgen receptor Mus musculus 72-89 28854419-9 2017 Blocking of AR by flutamide eliminated the stimulation effect of testosterone on kinase phosphorylation. Flutamide 18-27 androgen receptor Mus musculus 12-14 27866534-4 2016 The effect was partly reversed by the androgen receptor (AR) blocker flutamide (87.6%, P=0.004). Flutamide 69-78 androgen receptor Mus musculus 38-55 27866534-4 2016 The effect was partly reversed by the androgen receptor (AR) blocker flutamide (87.6%, P=0.004). Flutamide 69-78 androgen receptor Mus musculus 57-59 26217181-7 2015 Androgen receptor (AR) inhibition with 20 muM flutamide but not aromatase inhibition with 10 muM letrozole reduced basal and T-induced neurosphere growth in females, while only concurrent inhibition of AR and aromatase produced the same effect in males. Flutamide 46-55 androgen receptor Mus musculus 0-17 27482363-0 2016 Androgen receptor blockade using flutamide skewed sex ratio of litters in mice. Flutamide 33-42 androgen receptor Mus musculus 0-17 27482363-2 2016 The present study was conducted to elucidate the role of androgen receptor in this regard by blockade of androgen receptor using flutamide in female mice. Flutamide 129-138 androgen receptor Mus musculus 57-74 27482363-2 2016 The present study was conducted to elucidate the role of androgen receptor in this regard by blockade of androgen receptor using flutamide in female mice. Flutamide 129-138 androgen receptor Mus musculus 105-122 27482363-10 2016 In addition, the blockade of androgen receptor using flutamide appeared to enhance litter size. Flutamide 53-62 androgen receptor Mus musculus 29-46 27023109-7 2016 The association of siRNA TMPRSS2-ERG-squalene nanoparticles with flutamide displayed similar tumor growth inhibition as mice treated with siRNA TMPRSS2-ERG-squalene nanoparticles alone and was paralleled with modification of expression of ERG, androgen receptor, and cleaved-caspase-3. Flutamide 65-74 androgen receptor Mus musculus 244-261 26217181-7 2015 Androgen receptor (AR) inhibition with 20 muM flutamide but not aromatase inhibition with 10 muM letrozole reduced basal and T-induced neurosphere growth in females, while only concurrent inhibition of AR and aromatase produced the same effect in males. Flutamide 46-55 androgen receptor Mus musculus 19-21 22219300-6 2012 Simultaneous treatment with testosterone, H(2)O(2), and the androgen receptor (AR) antagonist, flutamide, reduces the effects of the hormone, pointing to a possible participation of the AR in the antiapoptotic effect. Flutamide 95-104 androgen receptor Mus musculus 60-77 23759306-6 2013 AR knockdown by RNAi or treatment with flutamide (an AR antagonist) in SCs inhibited the recovery of BTB-associated protein expression after 43 C heat treatment for 30 min. Flutamide 39-48 androgen receptor Mus musculus 0-2 23546600-11 2013 Androgen receptor antagonist, flutamide treatment prevents GFP/GRTH expression in Tg lines, demonstrating in vivo direct and indirect effects of endogenous androgen on LCs and GCs, respectively. Flutamide 30-39 androgen receptor Mus musculus 0-17 23399021-12 2013 Ectopic expression of AR in hepatocytes suppressed hepcidin transcription; this effect was blocked dose-dependently by AR antagonist flutamide. Flutamide 133-142 androgen receptor Mus musculus 22-24 23399021-12 2013 Ectopic expression of AR in hepatocytes suppressed hepcidin transcription; this effect was blocked dose-dependently by AR antagonist flutamide. Flutamide 133-142 androgen receptor Mus musculus 119-121 24742193-5 2014 In this study, we asked whether the nonsteroidal AR antagonist flutamide, delivered via a time-release pellet, could reverse or prevent androgen-dependent AR toxicity in three different mouse models of SBMA: the AR97Q transgenic (Tg) model, a knock-in (KI) model, and a myogenic Tg model. Flutamide 63-72 androgen receptor Mus musculus 49-51 24742193-7 2014 Given that flutamide effectively protects against androgen-dependent disease in three different mouse models of SBMA, our data are proof of principle that AR antagonists have therapeutic potential for treating SBMA in humans and support the notion that toxicity caused by polyQ-expanded AR uses at least some of the same mechanisms as normal AR before diverging to produce disease and muscle atrophy. Flutamide 11-20 androgen receptor Mus musculus 155-157 22219300-6 2012 Simultaneous treatment with testosterone, H(2)O(2), and the androgen receptor (AR) antagonist, flutamide, reduces the effects of the hormone, pointing to a possible participation of the AR in the antiapoptotic effect. Flutamide 95-104 androgen receptor Mus musculus 79-81 22219300-6 2012 Simultaneous treatment with testosterone, H(2)O(2), and the androgen receptor (AR) antagonist, flutamide, reduces the effects of the hormone, pointing to a possible participation of the AR in the antiapoptotic effect. Flutamide 95-104 androgen receptor Mus musculus 186-188 22276587-5 2012 Daily topical application of androgen receptor antagonist, flutamide, resulted in improved gap closure similar to orchiectomized controls and faster than orchidectomized mice treated with topical testosterone. Flutamide 59-68 androgen receptor Mus musculus 29-46 21846805-5 2011 In contrast, inhibition of AR signaling with flutamide from midpuberty had no effect on the mammary gland, but flutamide treatment from 12-21 wk increased ductal branching (P = 0.004) and proliferation (P = 0.03) of breast epithelial cells. Flutamide 45-54 androgen receptor Mus musculus 27-29 19605781-4 2009 Age at VO was examined in mice fed high-fat or low-fat diets from weaning and treated with the androgen receptor antagonist flutamide or vehicle (controls). Flutamide 124-133 androgen receptor Mus musculus 95-112 19790238-5 2010 The effect of flutamide (FLT) on the W741C mutant AR was examined with transactivation assays in vitro and with the oral administration of FLT to non-castrated mice harboring KUCaP-1 in vivo. Flutamide 14-23 androgen receptor Mus musculus 50-52 19790238-5 2010 The effect of flutamide (FLT) on the W741C mutant AR was examined with transactivation assays in vitro and with the oral administration of FLT to non-castrated mice harboring KUCaP-1 in vivo. Flutamide 25-28 androgen receptor Mus musculus 50-52 20689246-4 2011 METHODS: We tested whether the AR antagonist flutamide could block perinatal toxicity. Flutamide 45-54 androgen receptor Mus musculus 31-33 20709035-5 2010 Finally, the androgen receptor antagonist flutamide inhibited the increase in neuronal damage and sensorimotor impairment observed in testosterone treated mice. Flutamide 42-51 androgen receptor Mus musculus 13-30 20108248-6 2010 Administration of the androgen receptor inhibitor Flutamide blocked the basal and hCG stimulated GFP expression in Leydig cells. Flutamide 50-59 androgen receptor Mus musculus 22-39 20154177-5 2010 Organ and primary cell cultures of gubernacula showed that 5alpha-dihydrotestosterone (DHT) upregulated the expression of Rxfp2 which was abolished by the addition of an AR antagonist, flutamide. Flutamide 185-194 androgen receptor Mus musculus 170-172 17916626-7 2008 Addition of flutamide (1 microM) to T-treated EBs inhibited the T-induced proliferation of cardiomyocytes, confirming that, in this instance, androgens act via the classical AR-mediated genomic pathway. Flutamide 12-21 androgen receptor Mus musculus 174-176 19002196-5 2009 Testosterone effects on infarct size were blocked by the androgen receptor (AR) antagonist flutamide and further confirmed in young versus middle-aged mice. Flutamide 91-100 androgen receptor Mus musculus 57-74 19002196-5 2009 Testosterone effects on infarct size were blocked by the androgen receptor (AR) antagonist flutamide and further confirmed in young versus middle-aged mice. Flutamide 91-100 androgen receptor Mus musculus 76-78 18543106-7 2008 In vitro, AR could mediate beta-cell apoptosis, and AR antagonist flutamide contributed to beta-cell proliferation. Flutamide 66-75 androgen receptor Mus musculus 52-54 12403346-5 2002 Furthermore, castration or androgen receptor blockade with flutamide after trauma and hemorrhage in male mice showed similar beneficial effects. Flutamide 59-68 androgen receptor Mus musculus 27-44 15699175-8 2005 The effects of T4 in vivo and in vitro were reversed by the androgen receptor antagonist, flutamide, indicating that the regulatory effects of T4 were mediated through the androgen receptor. Flutamide 90-99 androgen receptor Mus musculus 60-77 15699175-8 2005 The effects of T4 in vivo and in vitro were reversed by the androgen receptor antagonist, flutamide, indicating that the regulatory effects of T4 were mediated through the androgen receptor. Flutamide 90-99 androgen receptor Mus musculus 172-189 16642786-14 2006 Moreover, testosterone-induced neuroprotection likely entails a linkage with the androgen receptor as is suggested by the flutamide-induced inhibition of the hormone activity. Flutamide 122-131 androgen receptor Mus musculus 81-98 15094514-5 2004 Pretreatment with the androgen receptor antagonist flutamide had no effect on seizure protection by 3alpha-androstanediol. Flutamide 51-60 androgen receptor Mus musculus 22-39 14652627-2 2003 In fact, it appears that endogenous testosterone inhibits wound healing and promotes inflammation since castration of male mice or systemic treatment with the androgen receptor antagonist flutamide accelerates cutaneous wound healing and reduces the inflammatory response. Flutamide 188-197 androgen receptor Mus musculus 159-176 12624004-2 2003 Female TGR(mREN2)27 rats harboring the mouse Ren-2 renin gene were treated with Flutamide (specific antagonist of the androgen receptor, 30 mg/kg per day) starting at 4 weeks of age. Flutamide 80-89 androgen receptor Mus musculus 118-135 11133514-7 2001 Flutamide, an androgen receptor antagonist, dose dependently blocked transgene expression in males and blunted the induction caused by testosterone in females. Flutamide 0-9 androgen receptor Mus musculus 14-31 11231319-2 2001 Moreover, prenatal administration of the androgen receptor antagonist, flutamide, equalizes developmental rates in male and female fetuses. Flutamide 71-80 androgen receptor Mus musculus 41-58 10590174-13 1999 While immunohistochemical studies showed that FLU was able to promote nuclear translocation of AR, Western analysis revealed that FLU, in contrast to T and DHT, failed to maintain the integrity of AR. Flutamide 46-49 androgen receptor Mus musculus 95-97 10590174-14 1999 The results demonstrate that (a) the endogenous androgens T and DHT regulate AR differently, suggesting a potential cellular mechanism that may contribute to the difference in neural target gene sensitivity to these androgens; (b) up-regulation of AR occurs only in the presence of agonists; (c) the mechanism of action of FLU in the brain involves inhibition of AR protein up-regulation normally seen in response to androgen; and (d) FLU promotes AR nuclear translocation but not augmentation of cellular AR populations. Flutamide 323-326 androgen receptor Mus musculus 248-250 10590174-14 1999 The results demonstrate that (a) the endogenous androgens T and DHT regulate AR differently, suggesting a potential cellular mechanism that may contribute to the difference in neural target gene sensitivity to these androgens; (b) up-regulation of AR occurs only in the presence of agonists; (c) the mechanism of action of FLU in the brain involves inhibition of AR protein up-regulation normally seen in response to androgen; and (d) FLU promotes AR nuclear translocation but not augmentation of cellular AR populations. Flutamide 435-438 androgen receptor Mus musculus 248-250 10590174-14 1999 The results demonstrate that (a) the endogenous androgens T and DHT regulate AR differently, suggesting a potential cellular mechanism that may contribute to the difference in neural target gene sensitivity to these androgens; (b) up-regulation of AR occurs only in the presence of agonists; (c) the mechanism of action of FLU in the brain involves inhibition of AR protein up-regulation normally seen in response to androgen; and (d) FLU promotes AR nuclear translocation but not augmentation of cellular AR populations. Flutamide 435-438 androgen receptor Mus musculus 248-250 10590174-14 1999 The results demonstrate that (a) the endogenous androgens T and DHT regulate AR differently, suggesting a potential cellular mechanism that may contribute to the difference in neural target gene sensitivity to these androgens; (b) up-regulation of AR occurs only in the presence of agonists; (c) the mechanism of action of FLU in the brain involves inhibition of AR protein up-regulation normally seen in response to androgen; and (d) FLU promotes AR nuclear translocation but not augmentation of cellular AR populations. Flutamide 435-438 androgen receptor Mus musculus 248-250 10590174-14 1999 The results demonstrate that (a) the endogenous androgens T and DHT regulate AR differently, suggesting a potential cellular mechanism that may contribute to the difference in neural target gene sensitivity to these androgens; (b) up-regulation of AR occurs only in the presence of agonists; (c) the mechanism of action of FLU in the brain involves inhibition of AR protein up-regulation normally seen in response to androgen; and (d) FLU promotes AR nuclear translocation but not augmentation of cellular AR populations. Flutamide 435-438 androgen receptor Mus musculus 248-250 10590174-14 1999 The results demonstrate that (a) the endogenous androgens T and DHT regulate AR differently, suggesting a potential cellular mechanism that may contribute to the difference in neural target gene sensitivity to these androgens; (b) up-regulation of AR occurs only in the presence of agonists; (c) the mechanism of action of FLU in the brain involves inhibition of AR protein up-regulation normally seen in response to androgen; and (d) FLU promotes AR nuclear translocation but not augmentation of cellular AR populations. Flutamide 323-326 androgen receptor Mus musculus 248-250 10590174-14 1999 The results demonstrate that (a) the endogenous androgens T and DHT regulate AR differently, suggesting a potential cellular mechanism that may contribute to the difference in neural target gene sensitivity to these androgens; (b) up-regulation of AR occurs only in the presence of agonists; (c) the mechanism of action of FLU in the brain involves inhibition of AR protein up-regulation normally seen in response to androgen; and (d) FLU promotes AR nuclear translocation but not augmentation of cellular AR populations. Flutamide 323-326 androgen receptor Mus musculus 248-250 10590174-14 1999 The results demonstrate that (a) the endogenous androgens T and DHT regulate AR differently, suggesting a potential cellular mechanism that may contribute to the difference in neural target gene sensitivity to these androgens; (b) up-regulation of AR occurs only in the presence of agonists; (c) the mechanism of action of FLU in the brain involves inhibition of AR protein up-regulation normally seen in response to androgen; and (d) FLU promotes AR nuclear translocation but not augmentation of cellular AR populations. Flutamide 323-326 androgen receptor Mus musculus 248-250